EBOV002, a Phase 1b, Placebo-controlled, Single-center Randomized Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of INO-4201 as a Booster Vaccination in Healthy Volunteers Who Have Previously Received the VSV-ZEBOV Vaccine

Project: Other project

Project Details

StatusFinished
Effective start/end date1/1/001/1/00

Funding

  • GuardRX: $12,294.00